Kodiak Sciences Inc.

The Company continues to monitor and reduce certain expenditures and plans to raise additional capital through approaches that include equity or debt financings, collaborations or a combination of similar transactions.

SEC original ↗Kodiak Sciences Inc. — 10-Q Quarterly report10-QAug 13, 2026

The Company believes that the existing cash and cash equivalents may not be sufficient to meet the anticipated operating and capital expenditure requirements for the 12 months following the date of this Quarterly Report on Form 10-Q.

SEC original ↗Kodiak Sciences Inc. — 10-Q Quarterly report10-QAug 13, 2026

Together, these efforts reflect our continued focus on disciplined execution as we advance our late-stage portfolio toward important clinical and regulatory milestones.

SEC original ↗Kodiak Sciences Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

Zenkuda (tarcocimab tedromer) — Advancing Toward Biologics License Application (BLA) Submission • Kodiak remains focused on regulatory, manufacturing and other BLA preparation activities supporting the planned development path for Zenkuda.

SEC original ↗Kodiak Sciences Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

We are focused on bringing new science to the design and manufacture of next-generation retinal medicines to prevent and treat the leading causes of blindness globally.

SEC original ↗Kodiak Sciences Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

ii SELECTED RISKS AFFECTING OUR BUSINESS Investing in our common stock involves numerous risks, including the risks described in Part II, Item 1A Risk Factors of this Quarterly Report on Form 10-Q, any one of which could materially adversely affect our business, financial condition, results of operations, and prospects.

SEC original ↗Kodiak Sciences Inc. — 10-Q Quarterly report10-QAug 13, 2026

Due to the significant resources required for the development of our product candidates, and depending on our ability to access capital, we must prioritize development of certain product candidates.

SEC original ↗Kodiak Sciences Inc. — 10-Q Quarterly report10-QAug 13, 2026

Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.

SEC original ↗Kodiak Sciences Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

and global economic markets may significantly impact Kodiak's business and operations, including its clinical trial sites, as well as the business or operations of its manufacturers, contract research organizations, or other third parties with whom Kodiak conducts business; as well as the other risks identified in the section entitled Risk Factors in Kodiak's Annual Report on Form 10-K for the year ended December 31, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Kodiak's subsequent filings with the Securities and Exchange Commission.

SEC original ↗Kodiak Sciences Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

Forward-looking statements are based on information available at the time those statements are made and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those in the forward-looking statements.

SEC original ↗Kodiak Sciences Inc. — 10-Q Quarterly report10-QAug 13, 2026

These statements reflect our current views and are based on assumptions and subject to risks and uncertainties, including those set forth in Part II, Item 1A Risk Factors and elsewhere in this Quarterly Report.

SEC original ↗Kodiak Sciences Inc. — 10-Q Quarterly report10-QAug 13, 2026

The forward-looking statements contained in this Quarterly Report, and other written and oral forward-looking statements made by us from time to time, are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, and you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.

SEC original ↗Kodiak Sciences Inc. — 10-Q Quarterly report10-QAug 13, 2026

ii SELECTED RISKS AFFECTING OUR BUSINESS Investing in our common stock involves numerous risks, including the risks described in Part II, Item 1A Risk Factors of this Quarterly Report on Form 10-Q, any one of which could materially adversely affect our business, financial condition, results of operations, and prospects.

SEC original ↗Kodiak Sciences Inc. — 10-Q Quarterly report10-QAug 13, 2026